Fendi Pharma Files IPO Prospectus: Pioneering AI-Driven PROTAC and Molecular Glue Platform for Targeted Protein Degradation Therapies
Fendi Pharmaceutical
Developer of New Immunotherapy Drugs for Refractory Diseases
FenDiPharmaIs InChina's first company to organically combine "AI+PROTAC+molecular glue" for new drug development, has established a proprietary PRODED targeted protein degradation drug platform and is using this platform to develop small-molecule innovative drugs for novel immunotherapies, with the aim of curing cancer and viral infectious diseases.
The 2004 Nobel Prize in Chemistry was awarded to three scientists for their discovery of the mechanism by which cells recycle waste proteins.That is, the ubiquitin-regulated protein degradation system. The 1996 Nobel Prize in Physiology or Medicine was awarded to scientists for their discovery of MHC proteins and their functions. FenDiPharma has creatively combined two mechanisms to develop small-molecule drugs that degrade pathogenic target proteins, with the aim of curing cancer and viral infectious diseases.
PRODED™ Small-molecule drugs for novel immunotherapy leverage the ubiquitin-proteasome pathway to induce degradation of pathogenic target proteins while using specific peptides from these pathogenic proteins to activate the immune system, thereby aiming to cure cancers and viral infectious diseases. Building on traditional protein degraders, FenDiPharma has pioneered the integration of protein degradation with an immune self-regulating mechanism and has taken the lead in...Artificial Intelligence (AI), Molecular SimulationTechnologies are applied to the development of new small-molecule drugs for novel immunotherapies, with the aim of accelerating the discovery of highly druggable small-molecule lead compounds and promoting the development of small-molecule drugs for novel immunotherapies.
FenDiPharma currently has 6 pipelines, including 3 self-developed pipelines and 3 collaborative pipelines. The self-developed pipelines...FD-001Approved by the National Medical Products Administration (NMPA) to commence clinical research for the treatment of AML; another is a molecular glue for lung cancer treatment, with an oral lead compound already obtained, showing degradation efficiency superior to existing PROTACs; another is a p53 modulator.
The FIC molecular glue in the collaboration pipeline degrades key target proteins in cardiovascular diseases. Its animal efficacy validation has outperformed first-line clinical drugs and it has been identified as a preclinical candidate compound, now entering preclinical development. Another program is a molecular glue for treating osteoporosis, currently under development. The third is the DAC production line.
FD-001It is an orally administrable molecular glue drug developed using FenDiPharma's proprietary "ProDeDrug" molecular glue rational design platform, andIn June this year, the clinical trial application was approved by the National Medical Products Administration.。Preclinical studies have shown its potential in treating hematological malignancies such as AML, MM, and NHL.In vivo efficacy studies of mouse xenograft tumor models have shown that intermittent dosing can significantly reduce tumor volume, further confirming the dosing frequency for patients.Importantly, FD-001 completely eliminated tumors in less than two weeks after administration, with no recurrence of tumors in the animals before the end of the study.This is due toFD-001 can degrade the transcription factor GSPT1 target protein in hematological tumors, thereby inducing apoptosis in tumor cells such as AML, MM, and NHL, and can eliminate cancer stem cells without affecting normal hematopoietic stem cells, overcoming the shortcomings of Venetoclax.
REVIEW
The 2nd Peptide Drug Industry Innovation Forum
（2023.4.15-16）
(2023.9.7-8)
(2023.3.11-12)
*This WeChat Official Account remains neutral on all original and reproduced content, statements, and viewpoints. The shared content is for public welfare purposes only. If any reproduced works or images have incorrect author source markings or involve infringement, original authors are kindly reminded to contact the editor for removal.
